Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

被引:0
|
作者
Florian A. Lempp
Leah B. Soriaga
Martin Montiel-Ruiz
Fabio Benigni
Julia Noack
Young-Jun Park
Siro Bianchi
Alexandra C. Walls
John E. Bowen
Jiayi Zhou
Hannah Kaiser
Anshu Joshi
Maria Agostini
Marcel Meury
Exequiel Dellota
Stefano Jaconi
Elisabetta Cameroni
Javier Martinez-Picado
Júlia Vergara-Alert
Nuria Izquierdo-Useros
Herbert W. Virgin
Antonio Lanzavecchia
David Veesler
Lisa A. Purcell
Amalio Telenti
Davide Corti
机构
[1] Vir Biotechnology,Department of Biochemistry
[2] Humabs Biomed SA,IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA
[3] a subsidiary of Vir Biotechnology,UAB)
[4] University of Washington,Germans Trias i Pujol Research Institute (IGTP)
[5] IrsiCaixa AIDS Research Institute,Department of Pathology and Immunology
[6] University of Vic–Central University of Catalonia (UVic-UCC),Department of Internal Medicine
[7] Catalan Institution for Research and Advanced Studies (ICREA),undefined
[8] Campus de la UAB,undefined
[9] Can Ruti Campus,undefined
[10] Washington University School of Medicine,undefined
[11] UT Southwestern Medical Center,undefined
[12] Vir Biotechnology,undefined
来源
Nature | 2021年 / 598卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
SARS-CoV-2 infection—which involves both cell attachment and membrane fusion—relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low levels in the respiratory tract1–3, suggesting that there may be additional mechanisms facilitating infection. Here we show that C-type lectin receptors, DC-SIGN, L-SIGN and the sialic acid–binding immunoglobulin-like lectin 1 (SIGLEC1) function as attachment receptors by enhancing ACE2-mediated infection and modulating the neutralizing activity of different classes of spike-specific antibodies. Antibodies to the amino-terminal domain or to the conserved site at the base of the receptor-binding domain, while poorly neutralizing infection of ACE2-overexpressing cells, effectively block lectin-facilitated infection. Conversely, antibodies to the receptor binding motif, while potently neutralizing infection of ACE2-overexpressing cells, poorly neutralize infection of cells expressing DC-SIGN or L-SIGN and trigger fusogenic rearrangement of the spike, promoting cell-to-cell fusion. Collectively, these findings identify a lectin-dependent pathway that enhances ACE2-dependent infection by SARS-CoV-2 and reveal distinct mechanisms of neutralization by different classes of spike-specific antibodies.
引用
下载
收藏
页码:342 / 347
页数:5
相关论文
共 50 条
  • [21] Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
    Wisnivesky, Juan P.
    Stone, Kimberly
    Bagiella, Emilia
    Doernberg, Molly
    Mendu, Damodara Rao
    Lin, Jenny J.
    Kale, Minal
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (10) : 3289 - 3291
  • [22] A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Liu, Hejun
    Yuan, Meng
    Huang, Deli
    Bangaru, Sandhya
    Zhao, Fangzhu
    Lee, Chang-Chun D.
    Peng, Linghang
    Barman, Shawn
    Zhu, Xueyong
    Nemazee, David
    Burton, Dennis R.
    van Gils, Marit J.
    Sanders, Rogier W.
    Kornau, Hans-Christian
    Reincke, S. Momsen
    Pruss, Harald
    Kreye, Jakob
    Wu, Nicholas C.
    Ward, Andrew B.
    Wilson, Ian A.
    CELL HOST & MICROBE, 2021, 29 (05) : 806 - +
  • [23] Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
    Pushparaj, Pradeepa
    Nicoletto, Andrea
    Sheward, Daniel J.
    Das, Hrishikesh
    Dopico, Xaquin Castro
    Vidakovics, Laura Perez
    Hanke, Leo
    Chernyshev, Mark
    Narang, Sanjana
    Kim, Sungyong
    Fischbach, Julian
    Ekstrom, Simon
    McInerney, Gerald
    Hallberg, B. Martin
    Murrell, Ben
    Corcoran, Martin
    Hedestam, Gunilla B. Karlsson
    IMMUNITY, 2023, 56 (01) : 193 - +
  • [24] Broadly neutralizing antibodies against SARS-CoV-2 variants
    Linqi Zhang
    National Science Open, 2022, 1 (01) : 24 - 31
  • [25] Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon
    Bahlawan, Omar
    Badra, Rebecca
    Semaan, Hanna
    Fayad, Nancy
    Kamel, Mina Nabil
    El Taweel, Ahmed N.
    Gomaa, Mokhtar R.
    Sirawan, Abeer
    Berry, Atika
    Mokhbat, Jacques
    Goldstein, Jimi
    Abdallah, Jad
    Kayali, Ghazi
    ARCHIVES OF VIROLOGY, 2022, 167 (07) : 1509 - 1519
  • [26] Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon
    Omar Bahlawan
    Rebecca Badra
    Hanna Semaan
    Nancy Fayad
    Mina Nabil Kamel
    Ahmed N. El Taweel
    Mokhtar R. Gomaa
    Abeer Sirawan
    Atika Berry
    Jacques Mokhbat
    Jimi Goldstein
    Jad Abdallah
    Ghazi Kayali
    Archives of Virology, 2022, 167 : 1509 - 1519
  • [27] Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies
    Vellas, Camille
    Del Bello, Arnaud
    Debard, Alexa
    Steinmeyer, Zara
    Tribaudeau, Laure
    Ranger, Noemie
    Jeanne, Nicolas
    Martin-Blondel, Guillaume
    Delobel, Pierre
    Kamar, Nassim
    Izopet, Jacques
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (01) : 139.e5 - 139.e8
  • [28] Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
    Wang, Lidong
    Mohlenberg, Michelle
    Wang, Pengfei
    Zhou, Hao
    CYTOKINE & GROWTH FACTOR REVIEWS, 2023, 70 : 13 - 25
  • [29] A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies
    Cerutti, Helena
    Bandini, Tommaso
    Castria, Marinunzia
    Cartocci, Alessandra
    Ricci, Veronica
    Tornesi, Stefania
    Bogi, Alessia
    Tesi, Giulia
    Soldatini, Claudia
    Toppi, Simona
    Brogi, Alessandra
    JOURNAL OF CLINICAL VIROLOGY, 2022, 147
  • [30] Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
    Zhou, Dongyan
    Zhou, Runhong
    Chen, Zhiwei
    IMMUNOTHERAPY ADVANCES, 2022, 2 (01):